On 19 Nov 2025, Venus Remedies recorded an intraday high of Rs.633, marking a 13.95% increase during the trading session. This milestone comes after a brief two-day decline, signalling a trend reversal that has seen the stock outperform its sector by 13.83% on the day. The stock’s day change stood at a notable 13.52%, while its intraday volatility was calculated at 10.9%, indicating active trading and investor engagement throughout the session.
Venus Remedies is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which reflects a strong upward momentum in its price trend. This technical positioning often suggests a robust market sentiment towards the stock within its sector.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- New Reliable Performer
- Steady quarterly gains
- Fertilizers consistency
Examining Venus Remedies’ performance over various time frames highlights its significant outperformance relative to the broader market benchmark, the Sensex. The stock’s 1-day performance was 14.23%, compared to the Sensex’s 0.38%. Over one week, Venus Remedies posted an 18.03% gain, while the Sensex recorded 0.62%. The 1-month and 3-month returns for the stock were 40.00% and 33.46%, respectively, versus Sensex returns of 1.24% and 4.10% for the same periods.
Longer-term data further illustrates the stock’s strong trajectory. Over the past year, Venus Remedies delivered a return of 115.65%, significantly outpacing the Sensex’s 9.56%. Year-to-date performance stands at 101.35%, compared to the Sensex’s 8.77%. Over three years, the stock has generated a return of 224.33%, while the Sensex posted 37.83%. The five-year and ten-year returns for Venus Remedies are 400.83% and 431.00%, respectively, compared to Sensex returns of 94.94% and 228.90% over the same durations.
These figures demonstrate Venus Remedies’ consistent ability to deliver market-beating returns across both short and long-term horizons, highlighting its resilience and growth within the Pharmaceuticals & Biotechnology sector.
Financially, Venus Remedies maintains a low average Debt to Equity ratio of zero, indicating a debt-free capital structure that may contribute to its financial stability. The company’s net profit growth is notable, with a 473.5% increase reported in the latest quarter ending September 2025. This period also saw the company declare very positive results, continuing a trend of positive quarterly outcomes for four consecutive quarters.
The Profit After Tax (PAT) for the quarter stood at Rs.20.13 crores, reflecting the substantial growth in profitability. Additionally, the company’s Return on Capital Employed (ROCE) for the half-year reached a high of 13.99%, while the Inventory Turnover Ratio for the same period was 6.58 times, both indicators of operational efficiency and effective asset utilisation.
Venus Remedies’ Return on Equity (ROE) is recorded at 10.5%, accompanied by a Price to Book Value of 1.2, suggesting an attractive valuation relative to its peers’ historical averages. The company’s Price/Earnings to Growth (PEG) ratio stands at 0.1, reflecting the relationship between its price, earnings, and growth metrics over the past year.
Venus Remedies caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- Comprehensive research report
- In-depth micro-cap analysis
- Valuation assessment included
Despite its size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund ownership may reflect a cautious stance or differing evaluation criteria within institutional investment circles.
Venus Remedies’ market capitalisation grade is rated at 4, and its Mojo Score stands at 77.0, with a recent adjustment in evaluation reflected by a grade change from Hold to Buy on 11 Nov 2025. The trigger for this revision was the stock reaching its all-time high on 19 Nov 2025, underscoring the significance of this price milestone in the company’s market assessment.
Overall, Venus Remedies’ journey to its all-time high of Rs.633 is characterised by strong financial metrics, consistent quarterly results, and sustained outperformance against market benchmarks. The stock’s current trading levels above key moving averages and its notable volatility on the day of the milestone further illustrate the dynamic nature of its market presence.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
